DC-Tn-MUC1

DC-Tn-MUC1 is a dendritic cell-based vaccine that targets the Tn-MUC1 glycopeptide. It consists of autologous dendritic cells loaded with the Tn-MUC1 glycopeptide, which represents a tumor-associated antigen. MUC1 is a glycoprotein normally expressed on the apical surface of ductal epithelial cells that becomes overexpressed, hypoglycosylated, and loses its polarization in cancer, carrying truncated carbohydrates known as Tn tumor antigens. In clinical trials, the vaccine has demonstrated safety and the ability to induce significant T-cell responses, with biological activity measured by increased PSA doubling time in prostate cancer patients.